Articles tagged with Cancer Patients
The CONCORD-2 study shows extreme variations in 5-year cancer survival estimates among countries, with some countries achieving high survival rates for certain cancers. Improvements are seen in developed countries and South America, but deficiencies remain in developing countries.
Researchers at University of Cincinnati have found a Food and Drug Administration-approved therapy effective in treating older and African American patients with non-small cell lung cancer. The study suggests that gefitinib improves quality of life and outcomes for this subgroup of patients, who often face limited treatment options.
The investigational drug AG-120 has demonstrated 'extremely promising' early phase 1 clinical trial results for patients with acute myeloid leukemia (AML) harboring IDH1 mutations. This finding builds on previous phase 1 results of a related drug, AG-221, and offers hope for the treatment of this high-risk population.
CPRIT awards UTSW faculty $22.5 million for groundbreaking research into leukemia, liver cancer, and anti-cancer immunotherapy, aiming to drive innovative therapies and better care for cancer patients. The grants will support investigations targeting promising new discoveries in cancer and commercial development.
A multi-centre clinical trial suggests that a combination of three targeted drugs may be more effective than one drug for certain patients with advanced BRAF-mutated colorectal cancer. The treatment, which includes encorafenib, cetuximab, and alpelisib, showed improved efficacy and extended progression-free survival in patients.
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumors have responded to the new drug E7438, a histone methyltransferase inhibitor. The drug has shown anti-tumor effects in four patients with refractory lymphoma and one patient with a malignant rhabdoid tumor, indicating potential for personalized medical therapy.
A $7.6 million grant supports the validation of molecular tests for early detection of colorectal cancer, aiming to reduce mortality rates. The international Dream Team will focus on developing a blood test to identify patients who can benefit from chemotherapy after surgery.
Patients with advanced papillary kidney cancer respond well to a combination of bevacizumab and erlotinib, with excellent response rates and long-lasting results. The treatment shows promise for patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) who have poor prognosis.
A phase I trial of AG-120, an oral inhibitor of mutant IDH1, has shown clinical activity in patients with advanced acute myeloid leukaemia (AML) and the IDH1 mutation. The drug reduced 2-HG levels to normal, allowing cells to mature into normal functioning cells.
Researchers at Cancer Research UK have identified over 400 areas of hidden faults in the human genome, which could conceal cancer-causing gene mutations. These 'blind spots' are difficult to detect using current gene-reading technology, highlighting opportunities for new diagnostic tests and treatments.
Researchers found that older patients with Alzheimer's or cancer were less likely to receive intensive procedures at the end of life. In contrast, black patients in high-hospital-intensity regions were more likely to undergo these procedures.
Researchers at NUS and their collaborators developed a novel scoring scheme that predicts the ability of cancer cells to spread. The system monitors epithelial-mesenchymal transition (EMT) mechanism, a key process in metastasis, and has shown good correlation with previously published EMT signatures.
A collaboration between St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and Institut Curie-Inserm identified frequent mutations in genes STAG2 and TP53 that define a subtype of Ewing sarcoma associated with reduced survival. The study provides critical insights into the genetic changes that d...
A novel medical-imaging technology called TexRAD has been shown to enable early diagnosis of bowel-cancer patients not responding to standard cancer therapy. The technology analyzes the texture of tumors, distinguishing patients with good prognosis from those with poor prognosis.
A University of Colorado Cancer Center study found that TAK-733, a next-gen melanoma drug, exhibited anti-cancer activity in 10 out of 11 patient tumor samples grown in mice. The drug showed significant shrinkage in tumors up to 100%, regardless of BRAF mutation status.
A pooled analysis of five cohort studies found that smoking before first cancer diagnosis increases risk of developing a second smoking-related cancer. Smoking survivors have up to a 5-fold higher risk of developing a second primary smoking-associated cancer compared to non-smokers.
A new study reveals that informed bladder cancer patients are more motivated to quit smoking, which can prolong their lives. Physicians can significantly impact this by educating patients about the link between smoking and their disease.
Researchers found that higher volume hospital and surgeon volume are associated with fewer post-operative complications and improved overall survival for bladder cancer patients. The study aims to identify processes and interactions leading to better outcomes, which could inform improvements in care at lower volume hospitals.
A new device has been developed to visualize and differentiate between cancer cells in the bloodstream, enabling a more focused understanding of tumour properties. This technology shows promise for better diagnosis and improved patient outcomes by identifying aggressive tumours and metastatic disease.
Researchers discovered that bisphosphonates can inhibit cancer spread in some women with breast cancer by attaching to calcifications in tumors and being devoured by immune cells. This finding could lead to new, more effective ways of using these drugs to treat certain cancers.
The incidence of colorectal cancer in people under 50 has increased, while those over 50 have seen a decline. The study found that the CRC incidence rate declined overall between 1975 and 2010, but rose among young adults, with the biggest increase seen in patients 20-34 years old.
Incidence rates of colon and rectal cancers among 20-34 year olds are projected to increase by 90% and 124.2%, respectively, by 2030. Lifestyle factors such as obesity and lack of physical activity contribute to the rising trend, while screening efforts in older patients have led to a decline in incidence rates among those over 50.
Patients with emergency-diagnosed lung cancer reported difficulties in seeing their general practitioner (GP), including lack of confidence and fear of diagnosis. Nearly half of the patients delayed seeking medical attention for over 12 weeks, highlighting the need for improved patient education and rapid-access diagnostic clinics.
Dr. John Carpten, Deputy Director of TGen, receives AACR Distinguished Lectureship for his work on cancer health disparities in minority populations. He will deliver a keynote lecture on November 9 at the AACR conference.
A trial revealed that patients with a specific type of esophageal cancer who received the lung cancer drug gefitinib survived longer, with some patients living up to six months beyond their initial treatment. The drug has shown promise as a targeted treatment for this disease.
A new trial has shown the Cytosponge test to be an accurate and safe way of diagnosing Barrett's Oesophagus. The test involves swallowing a sponge on a string and has been proven to be more effective than traditional endoscopy for detecting the condition.
A recent study published in The Journal of Experimental Medicine found that obesity can lead to lethal inflammation in response to certain anti-cancer therapies. This suggests that preclinical studies on young mice may not accurately predict outcomes in older patients, who are more likely to be overweight and develop cancer.
A study by Ben-Gurion University of the Negev found that preclinical oncology courses increased students' interest in specializing in oncology and empathy for cancer patients. The research suggests a need for medical schools to include such curriculum to develop communication skills and sensitivity towards death and dying.
A team of researchers has made a breakthrough in early diagnosis of invasive cancers, detecting lung cancer in patients at risk through circulating cancer cells in their bloodstream. This method could enable early surgical intervention and potentially improve patient survival.
The Cancer Health Literacy Study developed an evaluation tool called the Cancer Health Literacy Test (CHLT)-30 to measure cancer health literacy along a continuum. The study found that 18% of cancer patients have limited CHL, with an overrepresentation of African-American, undereducated and low-income patients.
A comprehensive review of 19,000 scientific papers identified more than 800 cancer-specific biomarkers that could lead to a single blood test for early detection of many types of cancer. The study aims to develop a screening test from a single blood sample for multiple cancer types.
Researchers developed a new strategy to detect bladder cancer using CD47, a protein that signals the immune system not to attack. The technique improves bladder cancer detection, guides precise surgery, and reduces unnecessary biopsies, increasing patients' quality of life.
A recent study published in Psycho-Oncology highlights the need for well-designed trials to determine the effectiveness of phone counseling interventions for cancer survivors. The research found that while some studies showed significant improvement, the results were not robust across multiple end points or studies.
Two studies found pediatric breast cancer patients experienced longer time between diagnosis and treatments, often diagnosed at later stages. Pediatric colon cancer patients had lower five-year survival rates than adults due to more aggressive tumors and treatments.
Rare cancer patients face scarce clinical evidence due to conventional trial methodologies requiring large patient numbers. The European Organisation for Research and Treatment of Cancer recommends alternative study designs and collaborative networking.
Researchers found that erlotinib, a targeted drug for advanced-stage lung cancer, can increase the aggressiveness of tumors in early-stage patients, leading to accelerated growth and decreased survival rates. The study suggests combining an EGFR inhibitor with a Notch inhibitor may overcome this effect.
Breast cancer patients taking brand name aromatase inhibitors had higher discontinuation rates and nonadherence compared to those on generic AIs. Higher copayments of $15-$30 per month were also linked to discontinued use.
UT Southwestern Medical Center is expanding its genetic screening program to 22 North Texas counties, serving underserved populations with HBOC and Lynch syndrome risk. The new grant will connect patients with genetic specialists through telemedicine, increasing accessibility and reducing transportation costs.
A Dartmouth study found that Diffuse Optical Spectroscopic Tomography (DOST) imaging can accurately predict which patients will respond well to neoadjuvant chemotherapy, enabling earlier and more effective treatment. This breakthrough could significantly improve disease-free survival rates for breast cancer patients.
A new study found that nearly two-thirds of patients treated for stage 3 colorectal cancer reported some measure of financial burden due to their treatment. The burden was greatest among patients who received chemotherapy and younger patients in low-paying jobs.
Two patients with cardiac lymphoma presented with brain metastasis, highlighting the need for identifying prognostic factors that predict brain relapse. Cardiac lymphoma is a rare condition often overlooked due to its potential for central nervous system metastasis.
A UCLA study found that patients with bladder cancer who did not receive optimal biopsies had a significantly higher risk of death from the disease. In fact, about half of patients' biopsies lacked sufficient material to accurately stage their cancer, leading to incorrect tumor staging and increased mortality rates.
Cancer patients often use dietary supplements without telling their doctors, which can lead to unneeded risks. Researchers emphasize the importance of open communication between patient and doctor to create a personalized treatment plan based on reliable information.
The Van Andel Research Institute-funded epigenetics dream team will focus on epigenetic mechanisms in cells to control gene expression. The team will move forward with more extensive clinical trials in other cancer types to improve upon the progress already made.
A long-term study of patients with HER2-positive breast cancer shows that adding trastuzumab to chemotherapy improves overall and disease-free survival by 37% and 40%, respectively. The regimen is now the standard of care for early stage HER2-positive breast cancer.
The University of Hawai`i Cancer Center has received a $3.5 million NCORP grant to improve cancer care and prevention among minority and underserved populations in Hawaii. The grant will fund clinical trials and research aimed at reducing cancer disparities and enhancing patient outcomes.
A large-scale population-based study found that removing the entire lobe of lung may offer better overall survival compared to partial resection and stereotactic ablative radiotherapy. The study also suggests that SABR may be a suitable alternative to surgery for elderly patients with multiple medical problems.
The EMA is exploring alternative approaches to clinical trials in rare cancers, recognizing the challenges of small sample sizes and the need for innovative methods. These discussions aim to enhance the evidence base for treatments in rare cancer patients, who face limited treatment options.
Researchers have identified key factors contributing to pancreatic cancer, including inherited genetic predisposition and a higher risk of developing other cancers. Active smoking was also found to significantly impact age at diagnosis.
A new technique using bioimpedance measurement reduces image degradation caused by respiratory motion during PET scans, enabling more accurate detection of cancers and heart conditions. This improved imaging quality can lead to better diagnosis reliability and treatment response monitoring.
Dartmouth researchers have identified nine traits that predict single nucleotide polymorphism (SNP) reproducibility without relying on P-values. The Replication Score (RS) model can select SNPs for validation and prioritization, improving the accuracy of genetic association studies.
A team of researchers at UT Southwestern Medical Center has identified PPARγ as a crucial metabolic pathway that can be targeted to stop the growth of lung cancer cells. By activating PPARγ with antidiabetic drugs, they were able to inhibit tumor cell division and induce oxidative stress, leading to cancer cell death.
Fertility experts advocate for making ovarian tissue and egg freezing options widely available to healthy women. The techniques have restored fertility in female cancer patients and enabled the birth of nearly 2000 babies without an increase in birth defects.
University of Minnesota researchers have identified microRNAs miR-182 and miR-503 that contribute to the development of colon polyps into cancerous tumors. By targeting these microRNAs, physicians may be able to provide earlier and more specialized treatment for patients with a higher risk of colon cancer.
A gene mutation that causes a rare premature aging disease could lead to the development of drugs that block rapid cell division in cancer. Researchers discovered a protein mutation that inhibits telomerase, allowing for the potential treatment of cancer and bone marrow failure.
The charity will focus on understanding the root causes of cancer problems in Yorkshire and developing strategies to reduce cancer incidence and mortality rates. The investment will also support research into improving screening methods and increasing access to clinical trials.
A survey of 80 female Greek oncologists found that women are under-represented in leadership positions, with team leaders being men in 82% of cases. The European Society for Medical Oncology launches a new initiative to promote the exchange of ideas among female oncologists and support women with cancer.
A survey of 895 doctors in Europe, South America, and Asia revealed that over three-quarters of oncology specialists believe their patients are not well-informed about treatment options. The majority (90%) use biomarker testing to choose treatments, but many identify cost or lack of reimbursement as key barriers.
A phase III trial showed that Rolapitant significantly reduced nausea and vomiting in patients receiving cisplatin-based chemotherapy. The study found that 72.7% of patients experienced complete response, with improved quality of life outcomes.
The phase III trials indicate that anamorelin is safe and well-tolerated in treating symptoms of advanced non-small cell lung cancer anorexia-cachexia. Patients experienced improvements in lean body mass, body weight, and patient symptoms/concerns regarding appetite over 12 weeks.